We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Blood Enzyme Indicates Risk of Heart Attack and Stroke

By Labmedica staff writers
Posted on 14 Jul 2008
Print article
A new test measures the amount of a specific enzyme that is present in blood when there is an active atherosclerotic process, which could lead to the rupture of plaque and cause a heart attack or a stroke.

Serologic markers with high specificity for advanced plaque can be used as a diagnostic tool in cardiovascular risk stratification. The new lipoprotein-associated phospholipase A2 (Lp-PLA2) blood test helps physicians to identify patients who could benefit from more aggressive therapy and it is especially recommended for intermediate and high-risk patients.

Lp-PLA2 is an inflammatory marker that is not affected by inflammation caused by infection or injury. Therefore, it is a more specific marker than C-reactive protein (CRP), which can be elevated from systemic infection, even when the vascular walls are healthy. High Lp-PLA2 in combination with high sensitivity (hs)-CRP increases the ability to determine risk level

SpectraCell Laboratories (Houston, TX, USA) has added the Lp-PLA2 to its cardiovascular range of products that are aimed at early detection of cardiovascular disease. Because 68% of heart attacks and strokes occur from blood clots, not narrowing of the arteries, and 50% of all heart attacks occur in patients with normal cholesterol values, the Lp-PLA2 test is often used in conjunction with advanced lipoprotein tests. SpectraCell's lipoprotein particle profile (LPP+) combines advanced cholesterol testing with additional independent risk factors such as Lp-PLA2, hs-CRP, insulin, and homocysteine.


Related Links:
SpectraCell Laboratories
New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
New
Multi-Function Pipetting Platform
apricot PP5

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.